Board of Directors

Q-linea’s BoD consist of a combination of entrepreneurs, inventors and industrial experienced persons representing the major owners of the company, and providing active support to the management.

Erika Kjellberg Eriksson
Erika Kjellberg Eriksson
Director since 2012, chairman of the board since 2018

Erika Kjellberg Eriksson has held board assignments and senior positions in pharmaceutical, biotech and medtech companies for more than 20 years. She has extensive experience from working in both listed and unlisted companies and vast board experience.

Born: 1962
Education: B.Sc in economics, Uppsala University (1985).
Other current assignments: Erika Kjellberg Eriksson is CEO of Nexttobe AB, chairman of the board of directors of Linum AB, Bioimics AB, Olink Bioscience AB, EQUIDx AB, Lumina Adhesives AB, Zetcity AB, Endovascular Development AB, AllgoTech AB, Capilet Genetics AB, Lokon Pharma AB, Olink Proteomics Holding AB and Allgotech Production AB. Member of the board of directors of Sweden Carnica Group AB, Delta Projects AB, Nexttobe AB, Vivolux AB, Bluefish Pharmaceuticals AB (publ), Tanea Medical AB and Olink Proteomics AB, and deputy boardmember of Bluefish Pharma AB and Bluefish Pharma Incentive AB.

Holdings in the Company: Erika Kjellberg Eriksson owns 32,000 shares in the Company.

Independent in relation to the company and its management, but not in relation to major shareholders.

Marianne Hansson
Marianne Hansson
Director since 2018

Marianne Hansson has 20 years’ experience in life sciences. She most recently served as CEO of Atlas Antibodies AB and prior to that as business development manager at Affibody Medical AB. She is a co-founder of Affibody AB, Atlas Antibodies AB, ScandiBio Therapeutics AB, ScandiEdge Therapeutics AB and Amylonix AB.

Born: 1963
Education: Doctor of technology in biochemistry, KTH Royal Institute of Technology (1998); MSc in chemical engineering, Royal Institute of Technology (1989).
Other ongoing assignments: Marianne Hansson is a member of the board of directors of Intervacc AB (publ) and Mariham Consulting AB, CEO of Mariham Consulting AB and external CEO of ScandiBio Therapeutics AB, ScandiEdge Therapeutics AB and Amylonix AB.

Holdings in the Company: Marianne Hansson does not own any shares in the Company.

Independent in relation to the company and its management and in relation to major shareholders.

Jon Heimer
Jon Heimer
Director since 2012 (chairman of the board 2013–2018)

Jon Heimer is an entrepreneur with a background in economics and marketing. He has 25 years’ experience in the development and commercialisation of medical devices, pharmaceuticals and biotech products. He has held senior positions in both Swedish and international biotech companies and several board assignments in the biotech industry.

Born: 1967
Education: Certified Director, StyrelseAkademien [year]; Market Economist DIHM, IHM Business School (2000); Marketing, Eductus (1995); Pharmaceutical Consultant, Läkemedelsindustriföreningen (LIF) and Representantföreningen for Utländska Farmaceutiska Industrier (RUFI) (1993); and Business Administration, Uppsala University (1993).
Other ongoing assignments: Jon Heimer is external CEO of Olink Proteomics Holding AB and of Olink Proteomics Inc. He is also member of the board of directors of Bioimics AB.

Holdings in the Company: Jon Heimer owns 106,680 shares in the Company.

Independent in relation to the company and its management, but not in relation to major shareholders.

Hans Johansson
Hans Johansson
Director since 2018

Hans Johansson has extensive experience and a broad contact network from his previous roles in the life sciences and diagnostics industry, most recently as vice president, head of Companion Diagnostics at Thermo Fisher’s Speciality Diagnostics Group. His previous positions include vice president global marketing and business development at Thermo Fisher’s Immuno Diagnostics Division and head of laboratories at Pharmacia Biotechnology AB.

Born: 1954
Education: MSc in chemical engineering
Other ongoing assignments: Hans Johansson is chairpman of the board of directors of Myrtila AB and Doloradix AB, a member of the board of directors of Uppsala Innovation Centre AB, Immunovia AB (publ) and Single Technologies AB, and a deputy boardmember of Duvbo Projektkonsult AB.

Holdings in the Company: Hans Johansson does not own any shares in the Company.

Independent in relation to the company and its management and in relation to major shareholders.

Ulf Landegren
Ulf Landegren
Director since 2012

Ulf Landegren is a professor of molecular medicine at Uppsala University and one of the founders of Olink Bioscience AB, from which Q-linea was spun off. He is also a member of the Royal Swedish Academy of Sciences and the European Molecular Biology Organization.

Born: 1952
Education: Associate professor of molecular biology (1996); postdoc at California Institute of Technology (1989); PhD in cellular immunology, Uppsala University (1984); medical degree, Uppsala University (1979).
Other ongoing assignments: Ulf Landegren is a professor of molecular medicine at Uppsala University. He also serves as a member of the board of directors of Olink Bioscience AB, Landegren Gene Technology AB and Olink Proteomics Holding AB and the Swedish Foundation for Strategic Environmental Research (Mistra), and deputy head of the Department of Immunology, Genetics and Pathology at Uppsala University.

Holdings in the Company: Ulf Landegren owns 24,920 shares in the Company. He owns an additional 192,800 shares in the Company through his wholly owned company Landegren Gene Technology AB.

Independent in relation to the company and its management, but not in relation to major shareholders.

Mats Nilsson
Mats Nilsson
Director since 2008 (chairman of the board 2008–2013)

Mats Nilsson is a professor of molecular diagnostics, has founded several companies in the biotech industry and is one of the founders of Q-linea. He has extensive board experience and currently serves as member of the board of Elos MedTech AB, which is listed on Nasdaq Stockholm.

Born: 1969
Education: Associate professor of molecular medicine, Uppsala University (2003); PhD in medical genetics, Uppsala University (1998); MSc in biology, Uppsala University (1998).
Other ongoing assignments: Mats Nilsson is Scientific Director and professor of biochemistry at the Science for Life Laboratory at Stockholm University. He also serves as chairman of the board of directors of ApiRays AB and member of the board of directors of EMPE Diagnostics AB, CartaNA AB and Elos MedTech AB and Biocyclica Holding AB.

Holdings in the Company: Mats Nilsson owns 444,000 shares in the Company. He owns an additional 53,320 shares in the Company through the related company Biocyclia Holding AB.

Independent in relation to major shareholders, but not in relation to the company and its management.

Marcus Storch
Marcus Storch
Director since 2018

Marcus Storch has extensive board experience. He also has leadership experience, including senior positions such as president of AGA AB. He also founded the Tobias Foundation.

Born: 1942
Education: MSc in electrical engineering, KTH Royal Institute of Technology (1967); honorary doctor at Karolinska Institute (1996).
Other ongoing assignments: Marcus Storch is chairman of the board of directors of Kebris AB and a director of the board of directors of Investment AB Öresund and Storch & Storch AB.

Holdings in the Company: Marcus Storch does not own any shares in the Company.

Independent in relation to the company and its management, but not in relation to major shareholders.

Per-Olof Wallström
Per-Olof Wallström
Director since 2018

Per-Olof Wallström has 46 years’ experience in the pharmaceutical and biotech industry and has held senior positions in the Nordic region and Europe at companies including Merck AB, Astra AB, Pharmacia AB and Bristol-Myers Squibb AB in the Nordics and Europe. He has also served as CEO of Karo Bio AB, Melacure Therapeutics AB and Q-Med AB.

Born: 1949
Education: MSc Pharm, Uppsala University (1972).
Other ongoing assignments: Per-Olof Wallström is chairman of the board of directors of Camurus AB and Camurus Development AB and a member of the board of directors of Arosia Communication AB.

Holdings in the Company: Per-Olof Wallström does not own any shares in the Company.

Independent in relation to the company and its management and in relation to major shareholders.